NCT07107074View on ClinicalTrials.gov

Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
Alzheimer Disease, Early Onset
Interventions
DRUG

AD04

Each patient will receive 6 single s.c. injections of IMP at monthly intervals over a 5-month treatment period.

DRUG

Placebo

Each patient will receive 6 single s.c. injections of Placebo at monthly intervals over a 5-month treatment period.

Trial Locations (3)

2100

Institute Neuromed, Korneuburg

15-756

Podlaskie Centrum Psychogeriatrii, Bialystok

85-133

Promente-Centrum Neurologii i Psychogeriatrii, Bydgoszcz

Sponsors
All Listed Sponsors
lead

ADvantage Therapeutics

OTHER

NCT07107074 - Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE | Biotech Hunter | Biotech Hunter